SCHEMBL4326753

SCHEMBL4326753

CC(c1ccccc1)N1CCN(c2cc(F)c(C=NNC(N)=S)cc2F)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.46
CYP2D6 P10635 1/20 0.40
MYC P01106 1/20 0.40
GAA P10253 5/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 4/20 0.39
ALDH1A1 P00352 4/20 0.39
NPSR1 Q6W5P4 2/20 0.39
ALOX12 P18054 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
USP2 O75604 1/20 0.39
MC4R P32245 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4326748 1.00 MAOB (0.46) MAOBCYP2D6MYCGAAL3MBTL1
SCHEMBL4336759 0.87 MAOB (0.45) MAOBGAAKDM4ESMN1; SMN2LMNA
SCHEMBL4336763 0.87 MAOB (0.45) MAOBGAAKDM4ESMN1; SMN2LMNA
SCHEMBL4332266 0.86 MAOB (0.44) MAOBCYP2D6MYCGAAL3MBTL1
SCHEMBL4332263 0.86 MAOB (0.44) MAOBCYP2D6MYCGAAL3MBTL1
SCHEMBL4327203 0.83 MAOB (0.44) MAOBCYP2D6GAAKDM4EMAPT
SCHEMBL4327199 0.83 MAOB (0.44) MAOBCYP2D6GAAKDM4EMAPT
SCHEMBL4334413 0.81 MAOB (0.41) MAOBGAAL3MBTL1KDM4EMAPT
SCHEMBL4334416 0.81 MAOB (0.41) MAOBGAAL3MBTL1KDM4EMAPT
SCHEMBL4331506 0.80 LMNA (0.45) MAOBCYP2D6GAAKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 2762/4885CYP2D6 2409/4885MYC 2720/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 3093/4885CYP2D6 2350/4885MYC 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.